Merck (NYSE: MRK) Receives European Approval of Elonva

Rochester, New York 11/21/2009 04:35 PM GMT (TransWorldNews)

Drug developer Merck & Co. (NYSE: MRK) said Friday a European advisory committee recommended approval for the company's fertility drug Elonva, according to Associated Press.

The Committee for Medicinal Products for Human Use of The European Medicines Agency made the recommendation. The European Commission will consider it when determining whether to approve the treatment. If approved, the injectable treatment could be sold in all European Union member states.

Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.

Shares of Merck rose 77 cents to $36.10 in morning trading.

Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.

About Us

Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.

Please click here to read the full disclaimer.